Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1629 1645 4100
This examiner grants 60% of resolved cases
William Justin Youngblood works in Art Unit 1629 of Tech Center 4100. He has 75 resolved cases and an allowance rate of 60.0 percent. The median days to allowance is 1210. The 60.0 percent allowance rate indicates a moderate level of success for applicants reaching a final resolution.
The interview lift is 41.7 percent. This high lift suggests that interviews are very effective for this examiner. Given the 60.0 percent baseline allowance rate and a median pendency of 1210 days, practitioners should prioritize interviews to address rejections and potentially shorten the prosecution timeline. The 41.7 percent lift is a strong indicator that the examiner is highly responsive to verbal discussion. With 75 resolved cases, the data shows a clear benefit to direct communication. Applicants should prepare for a long prosecution cycle of 1210 days and use interviews as a primary tool to resolve outstanding issues. This strategy can significantly improve the chances of a grant beyond the 60.0 percent baseline.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18728925 | PROCESS FOR SYNTHESIS OF GALBULIMIMA ALKALOID 18 AND COMPOUNDS USEFUL AS OPIOID RECEPTOR ANTAGONISTS AND AGONISTS | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18868132 | METHODS FOR COBINAMIDE SYNTHESIS | Non-Final OA | The Regents of the University of California |
| 18706266 | CANNABIGEROL FOR TREATMENT OF SEIZURES AND EPILEPSY | Non-Final OA | The Regents of the University of California |
| 18266525 | SMALL MOLECULES AND THEIR USE AS MALT1 INHIBITORS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 18867302 | PESTICIDAL COMPOSITIONS | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18728431 | COMPOUND COMPRISING RALTITREXED OR 5-MTHF LINKED TO A THERAPEUTIC AGENT, COMPOSITION, AND METHOD OF USE | Non-Final OA | PURDUE RESEARCH FOUNDATION |
| 18710002 | FLUCONAZOLE-COX INHIBITOR HYBRIDS: A DUAL-ACTING CLASS OF ANTIFUNGAL AZOLES | Non-Final OA | Ramot at Tel-Aviv University Ltd. |
| 18253229 | Methods of Using 4-Amino-N-[4-(Methoxymethyl)Phenyl]-7-(1-Methylcyclopropyl)-6-(3-Morpholinoprop-1-YN-1-YL)-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carboxamide for the Treatment of Tumors | Final Rejection | Taiho Pharmaceutical Co., Ltd. |
| 18023009 | NHE-1 INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | Final Rejection | ARES TRADING S.A. |
| 18266294 | Novel Bifunctional Molecules For Targeted Protein Degradation | Non-Final OA | Amphista Therapeutics Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy